研究单位：[1]Ferring Pharmaceuticals[2]Tongji Hospital Tongji Medical College of HUST Tongji Medical College Huazhong University of Science & Technology Wuhan, Hubei, China[3]The First Affiliated Hospital with Nanjing Medical University Nanjing, Jiangsu, China[4]ShengJing Hospital of China Medical University Shenyang, Liaoning, China[5]Sichuan Provincial People's Hospital Chengdu, Sichuan, China[6]Tianjin Medical University General Hospital Tianjin, Tianjin, China[7]Chinese PLA General Hospital Beijing, Beijing, China[8]Peking Union Medical College Hospital Beijing, Beijing, China[9]Peking University First Hospital Beijing, Beijing, China[10]Peking University People's Hospital Beijing, Beijing, China
研究目的：
Evaluate the efficacy and safety of of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program.
